273 related articles for article (PubMed ID: 37375748)
1. Ion Channels and Personalized Medicine in Gynecological Cancers.
Ramírez A; Ogonaga-Borja I; Acosta B; Chiliquinga AJ; de la Garza J; Gariglio P; Ocádiz-Delgado R; Bañuelos C; Camacho J
Pharmaceuticals (Basel); 2023 May; 16(6):. PubMed ID: 37375748
[TBL] [Abstract][Full Text] [Related]
2. A bioinformatics analysis of the clinicopathological and prognostic significance of
Zheng HC; Ren DH; Zhang CY; Chen Y; Zhang L
J Obstet Gynaecol; 2023 Dec; 43(1):2216280. PubMed ID: 37227120
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic analysis of the clinicopathological and prognostic significance of oocyte-arresting BTG4 mRNA expression in gynecological cancers.
Zheng HC; Xue H; Zhang CY; Zhang R
J Obstet Gynaecol; 2023 Dec; 43(1):2182672. PubMed ID: 36880525
[TBL] [Abstract][Full Text] [Related]
4. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
He Y; Wang Y; Ji C; Liu Y; Wu YM
Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
[No Abstract] [Full Text] [Related]
5. Bioinformatics analysis of the clinicopathological and prognostic significance of BAG3 mRNA in gynecological cancers.
Wang ZM; Zhang L; Ren DH; Zhang CY; Zheng HC
J Obstet Gynaecol; 2023 Dec; 43(2):2228899. PubMed ID: 37377218
[TBL] [Abstract][Full Text] [Related]
6. The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers.
Zhang CY; Zhang L; Wang ZM; Ren DH; Zheng HC
J Obstet Gynaecol; 2023 Dec; 43(1):2213764. PubMed ID: 37218920
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs as Potential Biomarkers in Gynecological Cancers.
Miśkiewicz J; Mielczarek-Palacz A; Gola JM
Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371799
[TBL] [Abstract][Full Text] [Related]
9. Role of microRNAs in gynecological pathology.
Gilabert-Estelles J; Braza-Boils A; Ramon LA; Zorio E; Medina P; Espana F; Estelles A
Curr Med Chem; 2012; 19(15):2406-13. PubMed ID: 22455593
[TBL] [Abstract][Full Text] [Related]
10. Strategies for Lynch syndrome identification in selected and unselected gynecological cancers.
Carnevali I; Sahnane N; Chiaravalli AM; Di Lauro E; Facco C; Facchi S; Casarin J; Ghezzi F; Sessa F; Tibiletti MG
Eur J Cancer Prev; 2022 Jul; 31(4):369-376. PubMed ID: 34519692
[TBL] [Abstract][Full Text] [Related]
11. The Role of Galectins in Tumor Progression, Treatment and Prognosis of Gynecological Cancers.
Chetry M; Thapa S; Hu X; Song Y; Zhang J; Zhu H; Zhu X
J Cancer; 2018; 9(24):4742-4755. PubMed ID: 30588260
[TBL] [Abstract][Full Text] [Related]
12. SOX9: Advances in Gynecological Malignancies.
Chen H; He Y; Wen X; Shao S; Liu Y; Wang J
Front Oncol; 2021; 11():768264. PubMed ID: 34881182
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential.
Frede J; Fraser SP; Oskay-Özcelik G; Hong Y; Ioana Braicu E; Sehouli J; Gabra H; Djamgoz MB
Eur J Cancer; 2013 Jul; 49(10):2331-44. PubMed ID: 23683551
[TBL] [Abstract][Full Text] [Related]
14. Gynecological Cancers-the Changing Paradigm.
Rema P
Indian J Surg Oncol; 2019 Mar; 10(1):156-161. PubMed ID: 30948892
[TBL] [Abstract][Full Text] [Related]
15. Eag1 channels as potential cancer biomarkers.
Rodríguez-Rasgado JA; Acuña-Macías I; Camacho J
Sensors (Basel); 2012; 12(5):5986-95. PubMed ID: 22778627
[TBL] [Abstract][Full Text] [Related]
16. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
17. Ion Channel Dysregulation in Head and Neck Cancers: Perspectives for Clinical Application.
Del-Río-Ibisate N; Granda-Díaz R; Rodrigo JP; Menéndez ST; García-Pedrero JM
Rev Physiol Biochem Pharmacol; 2021; 181():375-427. PubMed ID: 32789787
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of Curcuma oil and its terpenoids in gynecological cancers.
Zhang Y; Peng F; Yu C
Biomed Pharmacother; 2023 Jan; 157():114016. PubMed ID: 36395609
[TBL] [Abstract][Full Text] [Related]
19. Application of natural polysaccharides and their novel dosage forms in gynecological cancers: therapeutic implications from the diversity potential of natural compounds.
Li Y; Zhang C; Feng L; Shen Q; Liu F; Jiang X; Pang B
Front Pharmacol; 2023; 14():1195104. PubMed ID: 37383719
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
